xtremepicks.com: www.Xtremepicks.Com: Xtremepicks Alerts October 23, 2009 : ETEN, PCYG, SNRY and ADXS

Xtremepicks.com Alerts include E-18 Corp. (OTCBB: ETEN), Park City Group, Inc. (OTCBB: PCYG), Solar Energy Initiatives, Inc. (OTCBB: SNRY) and Advaxis, Inc., (OTCBB: ADXS)

E-18 Corp. (OTCBB: ETEN) trading at $0.70 per share on trading volume of 15,643 shares.

In a press release out on October 23, E-18 Corp. Releases In-Depth Corporate Overview Video

CEO Dr. John Salstrom Presents an Overview of Protectus Medical Devices and Its Revolutionary Safety Syringe

MINNEAPOLIS, Oct 23, 2009 -- E-18 Corp. (OTCBB: ETEN), through its wholly owned subsidiary, SquareOne Medical, Inc., doing business as Protectus Medical Devices ("Protectus Medical Devices"), today released an online overview video presented by Dr. John Salstrom, President and CEO of Protectus Medical Devices.

About E-18 Corp.

E-18 Corp., through its wholly owned subsidiary, SquareOne Medical, Inc., doing business as Protectus Medical Devices, develops and markets innovative safety medical percutaneous devices that, collectively, have the potential to dramatically reduce needlestick injuries for medical professionals worldwide. In the nearly $5 billion global hypodermic syringe market, the Protectus Safety Syringe, the Company's lead product, is the only fully automatic, self-sheathing hypodermic safety syringe that currently meets the functional definition of "Self-Sheathing" mandated by the U.S. Federal Government. None of the manufacturers of other devices on the market can make this claim. Protectus Medical Devices has successfully patented its automatic, self-sheathing hypodermic safety syringe product, and, based on the results of full comparison clinical trials, the Protectus Safety Syringe (formerly the SquareOne Safety Syringe) has received the required 510(k) permission from the U.S. FDA to manufacture and market the device in the U.S. More information about the Company may be found at www.protectusmedical.com.

Park City Group, Inc. (OTCBB: PCYG) trading at $2.61 per share on trading volume of 1,200 shares.

In a press release out on October 23, Park City Group Expects First Quarter Results to Exceed Expectations

Company Expects to Report EBITDA in Excess of $500,000 and Positive EPS

PARK CITY, Utah, Oct 23, 2009 -- Park City Group, Inc. (OTCBB: PCYG), a developer of patented, innovative retail supply chain solutions and services, today announced that it expects fiscal first quarter EBITDA and Earnings per Share to exceed expectations driven by strong revenue growth and prudent expense management.

About Park City Group

Park City Group is a trusted business solutions and services provider that enables retailers and suppliers to work collaboratively as strategic partners to reduce out-of-stocks, shrink, inventory and labor while improving profits, efficiencies, and customer service. Our innovative solutions provide trading partners a common platform on which they can capture, manage, analyze and share critical data, bringing greater visibility throughout the supply chain, and giving them the power to make better and more informed decisions. For more information, go to www.parkcitygroup.com.

Solar Energy Initiatives, Inc. (OTCBB:SNRY) trading at $0.40 per share on trading volume of 6,550 shares.

In a press release out on October 23, Solar Energy Initiatives, Inc. Announces Fourth Quarter and Year End 2009 Conference Call

PONTE VEDRA BEACH, Fla., Oct 23, 2009 -- Solar Energy Initiatives, Inc. (OTCBB:SNRY), executing on a grass roots campaign, "RENEW THE NATION", to help redeploy a portion of the U.S. work force and focus on reducing the world's dependence on fossil fuels by selling solar thermal and photovoltaic (PV) technologies, today announced will host a conference call on Thursday, October 29, 2009 at 4:15 p.m. Eastern Daylight Time to discuss the Company's financial and operational results for the Fourth Quarter and Year End 2009. During the call management will discuss the company's $100 million pipeline and the spin-off of Solar Park Initiatives.

About Solar Energy Initiatives, Inc.

Solar Energy Initiatives, Inc. (www.SolarEnergy.com) is executing its "RENEW THE NATION" campaign, intended to promote job growth nationwide via an aggressive grass roots effort. The main focus of RENEW THE NATION will be working with companies in the construction industry and related trades affected by the economic downturn to re-train and re-deploy their workforce into solar dealers, allowing this important national asset to meet the needs of the Solar Energy industry, the fastest growing industry in the world. We are executing on a multi-pronged approach to achieve our plan. This includes: continuing development of one of the fastest growing dealer networks in the U.S. that sells and installs solar solutions to homeowners and commercial customers; solar education and technical training to the private and public sectors, placing solar systems on large commercial buildings and selling the energy output to the owner/occupant(s) through Solar Power Purchase Agreements (PPAs); and becoming a developer of solar parks bringing together landowners, utilities and our corporate resources to build large photovoltaic installations.

Advaxis, Inc., (OTCBB: ADXS) trading at $0.139 per share on trading volume of 162,340 shares.

In a press release out on October 23, Advaxis Appoints Christopher Duignan Senior Vice President, Finance

NORTH BRUNSWICK, N.J., Oct 23, 2009 -- Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) biotechnology company, has announced the appointment of Christopher Duignan to the role of senior vice president, Finance, working alongside Advaxis CFO Fredrick Cobb, effective immediately.

About the Company

Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis' scientific advisory board. Advaxis is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer.

In a recent Advaxis Phase I clinical trial, a live Lm vaccine directed against the tumor-associated antigen HPV-16-E7 was safely administered to fifteen (15) women with advanced metastatic cancer of the cervix. Although this first trial of an Lm vaccine in humans was not designed or powered to prove efficacy, Advaxis believes an efficacy signal was observed that will be further explored in two (2) planned Phase II trials in the US and India in cervical cancer and its predecessor condition, cervical intraepithelial neoplasia (CIN). Advaxis now has nine (9) distinct cancer fighting constructs in various stages of development, both directly and with academic collaborators. For further information on the Company, please visit: www.advaxis.com.

Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.

Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm

CONTACT: Xtremepicks.com e-mail: Info@xtremepicks.com WWW: http://www.Xtremepicks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Related terms: academic, biotechnology, business, cancer, ceo, clinical, commercial, conference, corporate, dealer, earnings, ebitda, email, e-mail, energy, eps, fda, federal, finance, government, india, investment, investment opinion, labor, manufacturer, market, medical, new jersey, online, pennsylvania, pipeline, president, products, profit, retail, revenue, science, solar power, technology, training, trial, utilities, vaccine, video, web, women